Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Asset Writedowns and Impairment (2022)

Historic Asset Writedowns and Impairment for Abeona Therapeutics (ABEO) over the last 1 years, with Q4 2022 value amounting to $711000.0.

  • Abeona Therapeutics' Asset Writedowns and Impairment changed N/A to $711000.0 in Q4 2022 from the same period last year, while for Dec 2023 it was $711000.0, marking a year-over-year decrease of 7168.46%. This contributed to the annual value of -$1.1 million for FY2023, which is 14241.34% down from last year.
  • Abeona Therapeutics' Asset Writedowns and Impairment amounted to $711000.0 in Q4 2022.
  • In the past 5 years, Abeona Therapeutics' Asset Writedowns and Impairment ranged from a high of $3.3 million in Q1 2022 and a low of -$1.5 million during Q2 2022